Amid FDA chaos, approval of a rare disease drug gets delayed — again
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly…
Patients struggle as compounded GLP-1 access rapidly shrinks
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many…